Small Pharma Inc (DMT) is scheduled to report 4th quarter earnings on 06/08/2023.
Regarding Q4 estimates, Wall Street analysts expect Small Pharma Inc to post earnings of -C$0.01 per share. Last quarter, Small Pharma Inc beat earnings estimates, reporting EPS of -C$0.02 on estimates of -C$0.02. The stock rose by 10.00% the day after the last earnings release.
Year-to-date, DMT stock has fallen by -30.00%.
About Small Pharma Inc
Small Pharma Inc is a neuropharmaceutical company. It is committed towards the development of effective therapeutic treatments for mental health disorders. Small Pharma is developing N,N-dimethyltryptamine and a pipeline of novel patent-protected deuterium-enriched tryptamine compounds in combination with psychotherapy as potential rapid onset, sustained treatments for depression and other mental health disorders.
Stay up-to-date on earnings this week, with TipRanks’ Earnings Calendar.
